THE UNIVERSITY OF TEXAS 
M. D. ANDERSON CANCER CENTER 
Protocol Title: "Clinical Protocol for Modification of Oncogene and Tumor Suppressor 
Gene Expression in Non-Small Cell Lung Cancer (NSCLC)" 
Abstract 
1.0 Objectives Page 
2.0 Background and Rationale Page 
3.0 Safety Information Page 
4.0 Patient Eligibility Page 
5.0 Treatment Plan Page 
6.0 Pre-Treatment Evaluation Page 
7.0 Evaluation During Study Page 
8.0 Criteria for Response and Toxicity Page 
9.0 Criteria for Discontinuing Therapy Page 
10.0 Data and Protocol Management Page 
11.0 Reporting Requirements Page 
12.0 References Page 
Appendix A: Evaluation Before and During Therapy 
Appendix B: Zubrod Scale of Performance Status 
Appendix C: Toxicity Criteria 
Appendix D: Informed Consent 
STUDY CHAIRMAN: 
Jack A. Roth, M.D. 
Department of Thoracic Surgery 
[414] 
Recombinant DNA Research, Volume 16 
